205.83 USD
-9.21 (-4.28%)
205.83 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 89% to ASND. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 271.25. This target is 31.79% above the current price.
- ASND was analyzed by 23 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about ASND.
- In the previous month the buy percentage consensus was at a similar level.
- ASND was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-07 | TD Cowen | Reiterate | Buy -> Buy |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-11-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-10-17 | Raymond James | Initiate | Strong Buy |
| 2025-10-13 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-02 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-08 | UBS | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Stifel | Maintains | Buy -> Buy |
| 2025-08-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-08 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-29 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-06-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-06-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-03 | B of A Securities | Maintains | Buy -> Buy |
| 2025-05-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-05 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-05-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-05-02 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-05-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-04-16 | RBC Capital | Initiate | Outperform |
| 2025-03-18 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-25 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
ASCENDIS PHARMA A/S - ADR / ASND FAQ
What do analysts expect the price target to be for ASCENDIS PHARMA A/S - ADR (ASND)?
23 analysts have analysed ASND and the average price target is 271.25 USD. This implies a price increase of 31.79% is expected in the next year compared to the current price of 205.83.
Can you provide the consensus rating for ASCENDIS PHARMA A/S - ADR stock?
The consensus rating for ASCENDIS PHARMA A/S - ADR (ASND) is 88.6957 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for ASCENDIS PHARMA A/S - ADR stock?
The number of analysts covering ASCENDIS PHARMA A/S - ADR (ASND) is 23.